Franklin Covey Co. (FC) Forms $26.10 Double Bottom; Tonix Pharmaceuticals Holding Corp. (TNXP) Covered By 3 Bulls

Among 3 analysts covering Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Tonix Pharmaceuticals Holding Corp. had 6 analyst reports since August 20, 2015 according to SRatingsIntel. On Thursday, August 20 the stock rating was maintained by Oppenheimer with “Outperform”. The stock of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has “Buy” rating given on Thursday, November 9 by Roth Capital. On Monday, June 26 the stock rating was initiated by Aegis Capital with “Buy”. The stock of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has “Buy” rating given on Wednesday, November 4 by Cantor Fitzgerald. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, June 2. The firm earned “Buy” rating on Friday, August 18 by Roth Capital. See Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) latest ratings:

09/11/2017 Broker: Roth Capital Rating: Buy New Target: $6.0 Maintain
18/08/2017 Broker: Roth Capital Old Rating: Neutral New Rating: Buy Upgrade

Franklin Covey Co. (FC) formed double bottom with $24.80 target or 5.00% below today’s $26.10 share price. Franklin Covey Co. (FC) has $361.70 million valuation. The stock decreased 1.32% or $0.35 during the last trading session, reaching $26.1. About 62,683 shares traded. Franklin Covey Co. (NYSE:FC) has risen 33.77% since February 13, 2017 and is uptrending. It has outperformed by 17.07% the S&P500.

Tonix Pharmaceuticals Holding Corp. engages in developing pharmaceutical and biological products to address public health challenges. The company has market cap of $26.29 million. The Company’s lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder , which is in Phase 3 study in the military-related PTSD population. It currently has negative earnings. The firm is also developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder (PTSD); and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage.

The stock increased 0.30% or $0.01 during the last trading session, reaching $3.37. About 31,677 shares traded. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has declined 82.55% since February 13, 2017 and is downtrending. It has underperformed by 99.25% the S&P500.

Since September 1, 2017, it had 0 buys, and 2 sales for $69,744 activity. The insider PETERSON JOEL CLINTON sold $36,424.

Among 7 analysts covering Franklin Covey Company (NYSE:FC), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Franklin Covey Company had 8 analyst reports since November 5, 2015 according to SRatingsIntel. Roth Capital maintained Franklin Covey Co. (NYSE:FC) rating on Sunday, November 12. Roth Capital has “Buy” rating and $26.0 target. The stock of Franklin Covey Co. (NYSE:FC) earned “Market Perform” rating by William Blair on Thursday, November 5. Roth Capital maintained the stock with “Buy” rating in Thursday, November 5 report. The firm has “Buy” rating by Barrington given on Tuesday, January 9. On Thursday, November 5 the stock rating was maintained by TH Capital with “Buy”. Barrington Research downgraded the shares of FC in report on Wednesday, December 28 to “Mkt Perform” rating. The firm has “Buy” rating by FBR Capital given on Tuesday, November 7. The company was maintained on Friday, November 10 by B. Riley & Co.